arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AMARIN CORP PLCUK

AMRN
$14.31 ▼ -0.01 (-0.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

AMARIN CORP PLCUK faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.0B
Dividend Yield
Revenue Growth -42.0%
Op. Margin -28.5%
ROIC -2.6%
FCF / Share $0.02
Trailing P/E
Price / Book 13.6x
FCF Yield 0.1%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$42.21M
↓ -42.0%
Net Income Profit after all expenses
$-10.51M
↑ +33.0%
Operating Margin Operating profit as % of sales
-28.5%
↓ -13.3% 9th
FCF / Share Free cash flow per share
$0.02
↑ +4.0%
Long-Term Debt Long-term obligations
$9.39M
↓ -57.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
19
Returns
35
Financial Health
1
Cash Quality
17

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters